Celldex Shares Slip 15% as Safety Concerns Cloud Skin Drug Trial Win

Celldex Therapeutics (NASDAQ:CLDX) Trading Down 8.5% - Here's Why

Celldex Therapeutics (NASDAQ:CLDX) Shares Down 8.5% - Should You Sell?

Celldex shares slip 15% as safety concerns cloud skin drug trial win

(Rewrites throughout to add company comments, adds shares in paragraph 2, analyst comment in paragraph 5)- Celldex Therapeutics said on Tuesday its experimental

Celldex shares slip as safety concerns cloud skin drug trial ...

Celldex sinks as safety concerns cloud immune drug results

Though barzolvolimab displayed what one analyst described as the best efficacy results to date against chronic skin hives, treatment was also associated with two life-threatening anaphylaxis cases.

Celldex falls on safety concern, even as chronic hives drug succeeds in Phase 3 trials

Celldex said its experimental treatment barzolvolimab hit its primary endpoint in two Phase 3 trials, even as the readout raised safety concerns on two life-threatening cases of allergic reaction following administration of the drug. The ...